Overview

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Status:
Active, not recruiting

Trial end date:
2022-03-31

Target enrollment:

Participant gender:

Summary

This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid malignancies including differentiated thyroid carcinoma (single agent lenvatinib) and osteosarcoma (single agent and combination lenvatinib).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Eisai Limited

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Etoposide
Etoposide phosphate
Ifosfamide
Isophosphamide mustard
Lenvatinib